Equillium (EQ) remains a 'Hold' as it advances EQ504 for ulcerative colitis, with phase 1 trial initiation targeted for mid-2026. Company's Multi-Cytokine Platform enables selective cytokine targeting ...
Everyday Health on MSN
Ulcerative colitis and urgency: What you can do about it
ON THIS PAGEWhy Urgency Happens in UCSolutions for UC UrgencyWhen Urgency Is a Bigger ProblemMore than80 percent of people with ulcerative colitis (UC) experience bowel urgency that overwhelming, need ...
Everyday Health on MSN
Fulminant colitis: When an ulcerative colitis flare becomes a medical emergency
ON THIS PAGESymptomsComplicationsWhy Fulminant Colitis OccursWhat to Do During a Severe UC FlareAfter a Fulminant UC EpisodeFor some people with ulcerative colitis (UC), the symptoms are mild. But for ...
These easy weeknight-friendly dinner recipes are high in protein, heart-healthy, and avoid common trigger foods to help ...
Ulcerative colitis is a long-term disease that causes inflammation in the large intestine. It can lead to abdominal pain, diarrhea, bleeding, fatigue, and weight loss. For many people, the disease ...
When prescription prices keep climbing, patients are forced into impossible decisions — skipping doses, delaying treatment or choosing between medication and other basic needs. For people with Crohn’s ...
Researchers at Örebro University have identified blood markers that can indicate who is at risk of developing ulcerative ...
Researchers at örebro University have identified blood markers that can indicate who is at risk of developing ulcerative ...
Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s ...
In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results